‘NSABP B-55/BIG 6-13 [OlympiA]’ of page ‘NSABP B-55 / BIG 6-13’
NSABP B-55/BIG 6-13 [OlympiA]: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy Principal Investigators Charles […]
Read More